Primer: Akeso (9926 HK) - Jun 2026
Akeso is a leader in the development of innovative bispecific antibodies, with its core products, cadonilimab (PD-1/CTLA-4) and ivonescimab...
113 Views
𝛼SK or SearchENTITY
Akeso (9926 HK)
Akeso (9926 HK)
367
Analysis
Health Care • China
Akeso is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs. It develops treatments for major diseases such as cancer, autoimmune diseases, inflammation, and metabolic diseases, with key products including cadonilimab, ivonescimab, and penpulimab. The company was founded in 2012 and is headquartered in Zhongshan, Guangdong, China.
morex